Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly

Drugs and Aging

Volumn 24, Issue 4, 2007, Pages 275-292

  Noreddin, Ayman M ^a   Haynes, Virginia ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; ERTAPENEM; GATIFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MEROPENEM; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED DRUG RELEASE; DIABETES MELLITUS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG TOLERABILITY; DYSGLYCEMIA; ELDERLY CARE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HOSPITAL INFECTION; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROGENIC BLADDER; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PNEUMONIA; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE INFECTION; TENDINITIS; TENDON RUPTURE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

AGED; AGING; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; KIDNEY; RENAL INSUFFICIENCY;

EID: 34247209556     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724040-00002     Document Type: Review

References (116)

1. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985 Apr; 33 (4): 278-85
2. Chutka DS, Evans JM, Fleming KC, et al. Drug prescribing for elderly patients. Mayo Clin Proc 1995; 70 (7): 685-93
3. Strausbaugh LJ, Sukumar SR, Joseph CL. Infectious disease outbreaks in nursing homes: an unappreciated hazard for frail elderly persons. Aging Infect Dis 2003; 36: 870-6
4. Engelhart ST, Hanses-Derendorf L, Exner M, et al. Prospective surveillance for healthcare-associated infections in German nursing home residents. J Hosp Infect 2005; 60: 46-50
5. Gavazzi G, Krause K-H. Ageing and infection. Lancet Infect Dis 2002 Nov; (2): 659-66
6. Wang CY, Jerng JS, Cheng KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalized patients: clinical features, risk factors and outcomes. Eur Soc Clin Microbiol Infect Dis 2006; 12: 63-8
7. Rosenthal VD, Maki DG, Salomao R, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006, 92
8. Curtin J, Cormican M, Fleming G, et al. Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother 2003 Oct; 47 (10): 3145-8
9. Edmiston CE Jr, Goheen MP, Seabrook GR, et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006 Sep; 192 (3): 344-54
10. Greene CM, Kyaw MH, Ray SM, et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin Infect Dis 2006; 43: 141-50
11. McBean AM, Jung K, Hebert PL. Decreasing invasive pneumococcal disease in the elderly: a state level analysis. Vaccine 2006; 24: 5609-14
12. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug resistant Streptococcus pneumoniae. N Engl J Med 2006; 354 (14): 1455-64
13. Stalam M, Kaye D. Antibiotic agents in the elderly. Infect Dis Clin North Am 2004; 18: 533-49
14. O'Donnell JA, Hofmann MT. How to manage nursing home patients with or without chronic catheterization. Infect Dis 2002; 57 (5): 45-8
15. Ferrara AM, Fietta AM. New developments in antibacterial choice for lower respiratory tract infections in elderly patients. Drugs Aging 2004; 21 (3): 167-86
16. Nerella S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Therapy Pract 2004; 21 (13): 851-64
17. Flamminger A, Maibach H. Drug dosage in the elderly: dermatologic drugs. Drugs Aging 2006; 23 (3): 203-15
18. Wright RM, Warpula RW. Geriatric pharmacology: safer prescribing for the elderly patient. J Am Podiatr Med Assoc 2004; 94 (2): 90-7
19. Noreddin AM, Marras TK, Sanders K, et al. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500mg, 750mg and 1000mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004; 24: 479-84
20. Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalized patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005; 26: 120-5
21. Schmucker DL. Liver function and phase I drug metabolism in the elderly. Drugs Aging 2001; 18 (11): 837-51
22. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients. Clin Pharmacokinet 2005; 44 (10): 1009-34
23. Wyatt CM, Kim MC, Winston JA. Therapy insight: how changes in renal function with increasing age affect cardiovascular drug prescribing. Nat Clin Pract 2005; 3 (2): 102-9
24. Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 51: 1159-66
25. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics (PK/PD) of quinolones: maximizing bacterial eradication and preventing resistance. Res Adv Antimicrob Agents Chem 2004; 4: 39-67
26. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chem 2005; 55: 601-7
27. Craig WA, Bhavnani SM, Ambrose PG. The inoculum effect: fact or artifact? Diagn Microbiol Infect Dis 2004; 50: 229-30
28. Noreddin AM, Haynes VL, Zhanel GG. Pharmacokinetics and pharmacodynamics of the new quinolones. J Pharm Pract 2005; 18 (6): 1-12
29. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials [see comments]. JAMA 1998; 279 (2): 125-9
30. Tran JQ, Ballow CH, Forrest A, et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J Antimicrob Chem 2000; 45: 9-17
31. MacGowan AP, Bowker KE, Wootton M, et al. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrob Agents Chem 1999; 43 (7): 1560-4
32. Hershberger E, Rybak MJ. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chem 2000; 44 (3): 598-601
33. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chem 1998; 42 (3): 521-7
34. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chem 1999; 43 (3): 672-7
35. Park-Wylie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354: 1352-61
36. Park-Wyllie L, Shah BR, Juurlink DN. Correspondence. N Engl J Med 2006; 354: 2725-6
37. Ambrose PG, Bhavnani SM, Cirincione B, et al. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chem 2003; 52: 435-40
38. Yamada C, Nagashima K, Takahashi A, et al. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 2006 Dec 28; 553 (1-3): 67-72
39. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81
40. Lee SY, Kuti J, Nicolau D. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect 2005; 6 (3): 286-95
41. Itani KMF, Weigelt J, Li JZ, et al. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005; 26: 442-8
42. Niederman M. Principles of appropriate antibiotic use. Int J Antimicrob Agents 2005; 26 Suppl. 3: S170-5
43. DeRyke CA, Lee SY, Kuti JL, et al. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66 (1): 1-14
44. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987 Jan; 155 (1): 93-9
45. Begg EJ. Individualized drug and dose: the clinical pharmacologist's calling or curse? Exp Pharmacol Physiol 2005; 32: 975-8
46. Kirkpatrick CMJ, Begg EJ. Aminoglycoside dosage regimens after therapeutic drug monitoring. Clin Pharmacokinet 2002; 41 (10): 791-2
47. Hutschala D, Skhirtladze K, Zuckermann A, et al. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chem 2005; 49 (12): 5107-11
48. Capitano B, Mattoes HM, Shore E, et al. Steady state intrapulmonary concentrations of moxifloxacin, levofloxacin and azithromycin in older adults. Chest 2005; 125: 965-73
49. Xuan D, Nicolau DP, Nightingale CH. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents 2004; 23: 291-5
50. Kashuba ADM, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chem 1999; 43 (3): 623-9
51. Paterson DL, Robson JMB, Wagener MM, et al. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Geriatr Intern Med 1998; 13: 735-9
52. Rybak MJ, Abate BJ, Kang L, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chem 1999; 43 (7): 1549-55
53. Mohanty S, Kapil A, Dhawan B, et al. Bacteriological and antimicrobial susceptibility profile of soft tissue infections from Northern India. Indian J Med Sci 2004; 58 (1): 10-5
54. Kasiakou SK, Lawrence KR, Choulis N, et al. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 2005; 65 (17): 2499-511
55. Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006 Nov; 50 (11): 3556-61
56. Noreddin AM, Roberts D, Nichol K, et al. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chem 2002; 46 (12): 4029-34
57. Blumer JL. Evolution of a new drug formulation: the rationale for high dose, short course therapy with azithromycin. Int J Antimicrob Agents 2005; 26 Suppl. 3: S143-7
58. Liu P, Allaudeen H, Chandra R, et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemothe 2007 Jan; 51 (1): 103-9
59. Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomized, double blind study. BMJ 2006; 332: 1355-60
60. Katchman EA, Milo G, Paul M, et al. Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. Am J Med 2005; 188: 1196-207
61. Ong CT, Dandekar PK, Sutherland C, et al. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy 2005; 51: 339-46
62. Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. Clin Ther 2005; 27 (8): 1144-63
63. Greer N. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Baylor Univ Med Cent) 2006; 19: 155-61
64. Stahlmann R, Lode H. Fluoroquinolones in the elderly. Drugs Aging 2004; 20 (4): 289-302
65. Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chem 2000; 46: 669-83
66. Navarro AS, Gandarillas C-I, Lerma FA, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clin Pharmacokinet 2005; 44 (6): 627-35
67. Cappelletty DM, Zervos M. Levofloxacin use in the elderly: focus on pneumonia. Aging Health 2006; 2 (3): 371-82
68. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112: 275-85
69. Jumbe NL, Louie A, Miller MH, et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chem 2006; 50 (1): 310-7
70. Tam VH, Louie A, Deziel MR, et al. Bacterial population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005; 192: 420-8
71. Bhavani SM, Hammel JP, Jones RN, et al. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis 2005; 51: 31-7
72. Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41: S144-57
73. Morganroth J, DiMarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community acquired pneumonia. Chest 2005; 128: 3398-406
74. Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11 (1): 52-6
75. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006; 130: 11-5
76. Carcas AJ, García-Satué JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999; 65: 245-50
77. Khaliq Y, Zhanel G. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003; 36: 1404-10
78. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005; 65 (7): 949
79. Cohen AE, Lautenbach E, Morales KH, et al. Fluoroquinolone resistant Escherichia coli in the long-term care setting. Am J Med 2006; 119: 958-63
80. Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001; 32 Suppl. 1: S47-50
81. Gregg CR. Drug interactions and anti-infective therapies. Am J Med 1999; 106 (2): 227-37
82. Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol 1997; 37 (5): 765-71
83. Chu SY, Wilson DS, Guay DR, et al. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992 Nov; 32 (11): 1045-9
84. Chu SY, Granneman GR, Pichotta PJ, et al. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J Clin Pharmacol 1993; 33: 480-5
85. Hung IFN, Wu AKL, Cheng VCC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41: 291-300
86. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144: 415-20
87. Meagher AK, Ambrose PG, Grasela TH, et al. Pharmacokinetic/ pharmacodynamic profile for tigecycline: a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52: 165-71
88. Bryan CS, Talwani R, Stinson S. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112: 1657-64
89. Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 2005; 3 (1): 23-39
90. Musson DG, Majumdar A, Holland S, et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chem 2004 Feb; 48 (2): 521-4
91. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem and aztreonam. Mayo Clin Proc 1999; 74 (4): 420-34
92. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chem 2006; 50 (4): 1372-5
93. French G. Safety and tolerability of linezolid. J Antimicrob Chem 2003; 51 Suppl. S2: ii45-53
94. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chem 2003 Sept; 47 (9): 2775-80
95. Corallo C, Paull AE. Linezolid-induced neuropathy [letter]. Med J Aust 2002; 177 (6): 332
96. Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 2006; 26 (12): 1784-93
97. McKee EE, Ferguson M, Bentley AT, et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chem 2006 Jun; 50 (6): 2042-9
98. DeVriese AS, Van Coster R, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006; 42: 1111-7
99. Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005 Aug; 128: 545-52
100. Joukhadar C, Stass H, Müller-Zellenberg U, et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chem 2003 Oct; 47 (10): 3099-103
101. Bellman R, Kuchling G, Dehghanyar P, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol 2004; 57 (5): 563-8
102. Wagenlehner FME, Kinzig-Schippers M, Tischmeyer U, et al. Pharmacokinetics of ciprofloxacin XR (1000mg) versus levofloxacin (500mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Antimicrob Agents 2006; 27: 7-14
103. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chem 1996 Oct; 40 (10): 2375-9
104. Kuehnel TS, Schurr C, Lotter K, et al. Penetration of telithromycin into the nasal mucosa and ethmoid bone of patients undergoing rhinosurgery for chronic sinusitis. J Antimicrob Chem 2005; 55: 591-4
105. Zhanel GG, Johanson C, Hisanaga T, et al. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chem 2004; 54: 1072-7
106. Conte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Antimicrob Agents 2005; 25: 523-9
107. Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract [published erratum appears in Eur Respir J 1999 Nov; 14 (5): 1239]. Eur Respir J 1999 Jul; 14 (1): 221-9
108. Tomaselli F, Dittrich P, Maier A, et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 2003; 55: 620-4
109. Legat FJ, Krause R, Zenahlik P, et al. Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chem 2005 Oct; 49 (10): 4368-71
110. Boselli E, Breilh D, Cannesson M, et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4g/0.5g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30: 976-9
111. Laethem T, De Lepeleire I, McCrea J, et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob Agents Chem 2003 Apr; 47 (4): 1439-42
112. Burkhardt O, Majacher-Peszynska J, Borner K, et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J Clin Pharmacol 2005; 45: 659-65
113. Tomaselli F, Maier A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chem 2004 Jun; 48 (6): 2228-32
114. Tegeder I, Schmidtko A, Brautigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002; 71: 325-33
115. Rana B, Butcher I, Grigoris P, et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chem 2002; 50: 747-50
116. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chem 2003; 51: 1431-4